Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kami J Maddocks

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Haematologica|August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Haematologica|July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Pediatric Blood & Cancer|March 22, 2025
Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer CenterAllison M LeHanka, Ann M Kebede, Neda Amirmokhtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic LeukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
The Journal of Clinical Investigation|July 18, 2017
Ibrutinib treatment improves T cell number and function in CLL patientsMeixiao Long, Kyle Beckwith, Priscilla Do, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Haematologica|August 19, 2021
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J. Maddocks, Eva González-Barca, et al.
Haematologica|July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J Maddocks, Eva González-Barca, et al.
Pediatric Blood & Cancer|March 22, 2025
Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer CenterAllison M LeHanka, Ann M Kebede, Neda Amirmokhtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic LeukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
The Journal of Clinical Investigation|July 18, 2017
Ibrutinib treatment improves T cell number and function in CLL patientsMeixiao Long, Kyle Beckwith, Priscilla Do, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Leukemia & Lymphoma|October 3, 2018
Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originTalha Badar, Mehdi Hamadani, Veronika Bachanova, et al.
Pageof 5